BMI View: South Korea's biomedical research and development sector will continue to flourish in line with growing investments by local drugmakers. Facilitating this commitment is the strong support provided by the government as well as the opportunities to form drug discovery partnerships with leading US-based companies. As the sector develops, the broader economy will benefit and serve to support South Korea's export growth.
Headline Expenditure Projections
Pharmaceuticals: KRW16,590bn (USD15.8bn) in 2014 to KRW17,117bn (USD14.6bn) in 2015; +3.2% in local currency terms and -7.1% in US dollar terms. Forecast unchanged from previous quarter , negative growth in USD terms due to currency fluctuations
Healthcare: KRW108,205.8bn (USD102.8bn) in 2014 to KRW114,321.2bn (USD103.9bn) in 2015; +5.7% in local currency terms and -4.9% in US dollar terms. Forecast broadly unchanged from previous quarter.
|f = BMI forecast. Source: WHO, National Sources, BMI|
|Pharmaceutical sales, USDbn||14.714||15.754||14.630||14.015||14.809||16.187||17.585|
|Pharmaceutical sales, % of GDP||1.13||1.12||1.11||1.10||1.08||1.06||1.04|
|Pharmaceutical sales, % of health expenditure||15.7||15.3||15.0||14.6||14.3||14.0||13.7|
|Health spending, USDbn||93.593||102.757||97.710||95.774||103.456||115.491||127.993|
In Q116, South Korea ranks second out of the 19 countries surveyed in the Asia Pacific region. South Korea's score for its Rewards variable is high, indicating the country's favourable longer-term standing in terms of its pharmaceutical market development. However, we note Risks - particularly in relation to pharmaceutical pricing and reimbursement - will remain present, especially as the population ages and requires more public sector resources.
In September 2015, the country will revise health insurance coverage for foreign workers to prevent the misuse of benefits.
In August 2015, the South Korean government announced it will provide tourists with a 10% rebate on cosmetic surgery, effective from April 2016, in a bid to boost the tourism sector in the country.
In July 2015, the South Korean government spends less to support its citizens' healthcare costs compared with other OECD nations, according to a study by the National Assembly Research Service.
BMI Economic View: South Korea's Q315 real GDP grew by 2.6% y-o-y, reflecting a recovery from the previous quarter. Despite stronger growth, we have downgraded our forecast for 2015 real GDP growth to come in at 2.4% compared to 2.8% previously, as the recovery in the domestic economy will be insufficient to offset the slowdown in the external sector. We have also downgraded our real GDP forecast for 2016 to 2.8% from 3.0% previously, as external demand is likely to remain weak due to the slowdown in the Chinese economy.
BMI Political View: South Korea's inability to settle ongoing disputes with its immediate neighbours, North Korea, Japan, and China, will severely limit its attempts at becoming a regional middle power. Furthermore, Seoul will find it increasingly difficult to balance its interests between the US and China, as the latter two step up their geopolitical competition in the Asia-Pacific region.
The South Korea Pharmaceuticals & Healthcare Report features BMI Research's forecasts for drugs and healthcare expenditure and imports and exports, focusing on the growth outlook for the prescription, OTC, patented drugs and generics market segments.
BMI's South Korea Pharmaceuticals & Healthcare Report provides industry professionals, strategists, company executives, investors, analysts and sales/marketing heads with independent forecasts and competitive intelligence on the South Korea pharmaceutical and healthcare industry.
- Benchmark BMI's pharmaceutical and healthcare market forecasts for South Korea, to test other views - a key input for successful budgeting and strategic business planning in the Korean pharmaceutical and healthcare market.
- Target business opportunities and risks in the Korean pharmaceutical and healthcare sector through our reviews of latest industry trends, regulatory changes and major deals, projects and investments in South Korea.
- Assess the activities, strategy and market position of your competitors using our company profiles (including SWOTs, KPIs and latest activity) and competitive landscape tables.
BMI Industry View
An at-a-glance perspective on the latest regulatory developments, key forecast indicators and major corporate developments, covering the prescription, OTC and generics markets. The pharmaceuticals and healthcare SWOT outlines strategic factors that affect the basic assumptions underpinning BMI’s forecast analysis, and taken together with BMI’s political, economic and business environment SWOTs, it gives a complete overview of market climate.
BMI Industry Forecast Scenario
Industry forecasts to end-2019 for all key indicators, supported by explicit assumptions, plus analysis of key downside risks to the main forecasts:
- Healthcare: Total healthcare expenditure (USDbn), healthcare expenditure (% of GDP), healthcare expenditure per capita (USD), hospital beds, doctors, and birth & mortality rates (all per ‘000 population).
- Pharmaceutical Market: Drug expenditure in USDbn, % of GDP and per capita (USD).
- Patented Drug Market: Prescription drug sales (USDbn & % of total sales).
- Generic Drug Market: Generic product sales (USDbn), generic sales (% of total sales).
- OTC Drug Market: OTC sales (USDbn & % of total sales).
- Macroeconomic Forecasts: Nominal and real GDP, % real GDP growth, % private consumption growth, % industrial output growth, % consumer price index, % GDP price deflator, exports, imports, trade balance, current account balance, foreign direct investment, exchange rate against USD, government expenditure and external debt.
BMI’s Pharmaceuticals and Healthcare Risk Reward Index
BMI’s Risk Reward Index provides investors (both national and multinational) looking for opportunities in the region with a clear country-comparative assessment of the market’s risks and potential rewards. Each of the country markets are scored using a sophisticated model that includes more than 40 industry, economic and demographic data points to provide indices of highest to lowest appeal to investors, with each position explained.
A snapshot of key market characteristics, including total size of the pharmaceuticals and healthcare segments, growth drivers, leading therapeutic areas and the competitive landscape
A focus on government healthcare reforms, epidemiological trends, mergers and acquisitions, product launches, market entries, FDI activity, R&D, biotechnology, clinical trials and supply chain issues.
Details of the industry regulatory framework and key legislation covering the licensing of new products/services, pricing and reimbursements, intellectual property, taxation and advertising, as well as analysis of the overall regulatory burden.
The competitive landscape section provides comparative company analyses and index by USD sales and % share of total sales – for the total pharmaceutical sector, as well as the OTC, generics and distribution sub-sectors.
Examines the competitive positioning and short- to medium-term business strategies of key industry players. Strategy is examined within the context of BMI’s industry forecasts, our macroeconomic views and our understanding of the wider competitive landscape to generate Company SWOT analyses. The latest financial and operating statistics and key company developments are also incorporated within the company profiles, enabling a full evaluation of recent company performance and future growth prospects.
*Company profiles are not available for every country. Those reports instead contain information on the current activities of prominent companies operating in the market.